Key Highlights
- Revenue increased 11.6% to $382,000 in FY2019
- Net profit declined 16.0% to $326,000
- Underlying profit of $227,000 indicates adjusted earnings pressure
- Earnings per share (EPS) of 65.2 cents
- Full-year dividend per share (DPS) of 22.7 cents
Financial Performance
Ryman Healthcare's FY2019 results indicate a divergence between revenue growth and profitability. The company reported revenue of $382,000, representing an 11.6% increase from the prior year, suggesting continued expansion in its core healthcare operations. However, this top-line growth appears not to have translated into proportional profit expansion.
Net profit fell to $326,000, down 16.0% year-on-year, which suggests that cost pressures or operational challenges may have offset revenue gains. The underlying profit figure of $227,000 indicates that adjusted earnings—potentially excluding one-off items—also faced headwinds during the period. These dynamics suggest a margin compression environment, though specific cost breakdowns are not available from the data provided.
Earnings Analysis
The divergence between revenue growth and profit decline warrants attention. Based on available data, the 11.6% revenue increase contrasts sharply with the 16.0% net profit contraction, indicating that operating leverage moved in an unfavourable direction during FY2019. This pattern suggests that either cost of sales, operating expenses, or other line items grew faster than revenue, or that one-off charges impacted the bottom line.
Dividend Update
Ryman Healthcare maintained dividend distributions to shareholders during FY2019, with a full-year DPS of 22.7 cents. Recent dividend history indicates interim payments of 11.5 cents, 10.8 cents, and 8.8 cents across recent periods, suggesting a variable interim dividend approach. The maintenance of dividend payments despite profit contraction may indicate management confidence in underlying cash generation or a commitment to shareholder returns.
What This Means
Ryman Healthcare's FY2019 results present a mixed picture for stakeholders. Revenue expansion indicates ongoing demand within the healthcare sector, yet profit compression raises questions about operational efficiency and cost management. The company's governance score of 67.59/100 (rated as "Good") suggests reasonable standards of corporate oversight, though investors may wish to monitor management's response to profitability pressures in subsequent periods. The healthcare sector remains subject to regulatory, demographic, and cost inflation dynamics that warrant ongoing scrutiny.
---
This article was generated from structured NZX data by NZXplorer's automated reporting system. It is provided for informational purposes only and does not constitute financial advice. Data sourced from NZX company announcements and public filings. Always consult a licensed financial adviser before making investment decisions.